No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
PFE250117P60000
- 33.60
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open33.60Pre Close0 Volume0 Open Interest60.00Strike Price0.00Turnover0.00%IV1.71%PremiumJan 17, 2025Expiry Date33.14Intrinsic Value100Multiplier-10DDays to Expiry0.46Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Pfizer Is Maintained at Neutral by Citigroup
Citi Maintains Pfizer(PFE.US) With Hold Rating, Announces Target Price $29
Pfizer Analyst Ratings
Pfizer Plans To Present Latest Results From Its Genitourinary Portfolio At ASCO GU Cancers Symposium Taking Place February 13-15 In San Francisco, California
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
Express News | Pfizer to Showcase Advancements Across Genitourinary Cancers at Asco Gu Cancers Symposium